ABOUT US
We strive to improve the patient’s ability to take control of their own mental health
We explore experimental therapies that go beyond traditional health care.
WHAT WE DO
Mind Therapeutics conducts psilocybin micro and trip-dose clinical trials with our advanced biotechnology data collection process.
We focus on anxiety, depression, addiction, sleeping disorders and PTSD as the mental health crisis has exploded in recent years.
Our industry-leading neuroscientist and medical experts are poised to transform the standard of care for mental health.
Media
Our Results:
Our clinical research may allow us to transcend current methodologies, lower costs as we increase access for valuable treatments, and establish new standards for mental health care.
Mission
We aim to explore all the possibilities of care for the health of the mind using advanced biotechnology and industry-leading expertise. We will work openly and look to improve the outlook for mental health to improve the lives of those in need.
Leadership
Katarina Maloney
Chief Executive Officer
Katarina is a biotechnology leader in business development, strategic operations, supply chain, and product management. She completed two simultaneous bachelor’s degrees in European Studies/Political Science and Foreign Language. She attended leadership programs at Cornell University and Crescom Leadership Training Institute and is experienced in the hemp and cannabis industries.
Michael Pierce, DC, DACNB
Chief Medical Strategy Officer
Dr. Michael Pierce specializes in neurology, clinical neurochemistry, and neuroautoimmune support for 25 years. Dr. Pierce has a Bachelor of Science and is a professor at Carrick Institute of Clinical Neuroscience and at Northwestern Health Sciences University. He attended Carrick Institute of Clinical Neuroscience for his post-doctorate in Neurology.
Olga Melnik
CPSM, PMP
Chief Operations Officer
Olga Melnik is a business operation, clinical operations, supply chain, logistics, tracking, record and project management, and pharmaceuticals field expert. She holds a Bachelor of Science in Supply Chain Management from Universities in Uzbekistan and the United Kingdom.
Scientific Leadership
Dr. Fred Starr, MD, FAACAP
Chief Psychiatry Science Officer
Dr. Starr is a neuroscientist and psychiatrist specializing for 40 years in Brain-Computer Interface and Neurofeedback. He invented and patented a method to collect and analyze EEG. He founded a psychiatry practice that was the first to deliver large-scale alternative therapies for mental health healing.
Xenia Kachur
Chief Technology Officer
Xenia is our expert biomedical engineer and biohacker. She earned a graduate degree in Biomedical Engineering from the University of Arizona. She is a medical device development expert in the Cannabis space.
Yuri Kropotov, PhD
Chief Medical Officer
Yuri Kropotov is a neuroscientist, book author, and a “Russian Nobel Prize” recipient with award-winning brainwave research earning three doctorates in theoretical physics, philosophy, and neurophysiology.
Bernard Wandernoth, PhD
Chief Engineering Officer
Mrs. Wandernoth is a Switzerland signals engineer of Human Brain Interface (HBI) brain wave database and the EEG and ERP hardware and software system for QEEG and ERP analysis and has extensive international experience in compliance and regulations.
Partnerships
83BarGo is our recruitment agency that finds appropriate clinical trial subjects using a simple and thorough online system. They will track the data for all subjects throughout the trial and will even follow-up with subjects long-term. This is an important part of our clinical studies to fully optimize the data and research.
COEUS Consulting Group maximizes our brand success and product access with their expert insight into customer decision-making. They are experts in pharmaceutical product brands and have innovative methods to employ customer engagement to educate on disease burden, therapy, and quality of care. Their health economics and market specialists and have launched an extensive number of products and have managed the lifecycle of their portfolio offerings. COEUS offers actionable insights and is important as we develop our drugs and gain market support.
We will be using psilocybin plant genome in our trials to ensure quality, keep costs low, and help benefit the environment. Cellibre helps us to provide pharmaceutical grade products that we can track with VeChain during all phases of clinical and FDA trials. We can compare profiles and outcomes of traditionally grown to cell-based genome and find the best use of our products. We favor agricultural plant science as a system that promotes environmental preservation while securing quality.
CereScan, CereMetrix, and CereLaw offer quantitative SPECT imaging and brain analytics and combine their data with their database of conditions and subjects. They include neuroradiological reports with 3 dimensional images that pick up what MRI and CT scans usually miss. CereScan analyses the data of the sub-regions of the basal ganglia, blood flow, and a full assessment of the brain. We can provide a specific treatment plan with these incredible brain measurements.
Clinlogix provides clinical research support that integrates technology in our clinical trials. They will track subjects using lifetime, crossover, and combination therapy studies. Clinlogix works with a highly regarded network of medical and scientific advisors that enables them to carry out quality research and full-scale clinical trials. Their partnership with clinical specialisits ensures proper assessment of symptoms and neurological conditions and supports proper therapeutics and enrollment in the neurology studies. They have extensive market experience and understand complex biopharmaceutical goods in order to develop quality products.
VeChain allows us to show patients, consumers, and the public market every step of the supply chain to promote transparency and accountability. We want complete visibility during clinical trials to ensure quality and safety by showing the medicines we are using, how they impact the mental health of patients, and showing end-to-end tracking of production. It is also important to gain traction with legalization efforts.
Join Our study
We at Mind Therapeutics are united by our commitment to improve patient experience and healing in mental health care.
Below is a submission link to join our study for those who are experiencing Anxiety, Depression,PTSD and Addiction and looking for alternative, experimental therapies.
Investors
Join us by investing in our journey to improve mental
health and happiness. Sign up for regular updates,
press releases, and announcements that are
delivered right to your inbox.
Newsletter
Join our Healing Community by signing up for a newsletter to receive the latest news and updates of our work and discoveries.
